Farah Champsi - Net Worth and Insider Trading

Farah Champsi Net Worth

The estimated net worth of Farah Champsi is at least $13 Million dollars as of 2024-11-13. Farah Champsi is the Director of Kite Pharma Inc and owns about 63,664 shares of Kite Pharma Inc (KITE) stock worth over $11 Million. Farah Champsi is also the Director of Chimerix Inc and owns about 1,714,330 shares of Chimerix Inc (CMRX) stock worth over $2 Million. Details can be seen in Farah Champsi's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Farah Champsi has not made any transactions after 2017-06-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Farah Champsi

Farah Champsi Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Farah Champsi owns 24 companies in total, including Allakos Inc (ALLK) , Sutro Biopharma Inc (STRO) , and Kite Pharma Inc (KITE) among others .

Click here to see the complete history of Farah Champsi’s form 4 insider trades.

Insider Ownership Summary of Farah Champsi

Ticker	Comapny	Transaction Date	Type of Owner
ALLK	Allakos Inc	2018-07-18	10 percent owner
STRO	Sutro Biopharma Inc	2018-09-26	10 percent owner
KITE	Kite Pharma Inc	2017-10-03	director
		2014-11-19	10 percent owner
		2015-06-05	10 percent owner
		2015-05-06	10 percent owner
		2014-01-30	director & 10 percent owner
		2014-03-26	10 percent owner
		2013-06-25	10 percent owner
		2014-07-29	10 percent owner
		2014-05-02	10 percent owner
		2014-01-30	10 percent owner
		2013-10-23	director & 10 percent owner
		2013-05-28	director
		2012-10-15	10 percent owner
		2010-06-30	other: Former 10% Owner
		2007-08-17	10 percent owner
		2008-08-29	10 percent owner
		2009-09-03	other: No longer 10% owner
		2007-05-07	10 percent owner
		2004-02-19	other: See footnotes
		2009-04-03	10 percent owner
		2020-11-17	director
		2020-11-17	director

Farah Champsi Latest Holdings Summary

Farah Champsi currently owns a total of 2 stocks. Among these stocks, Farah Champsi owns 63,664 shares of Kite Pharma Inc (KITE) as of June 16, 2017, with a value of $11 Million and a weighting of 87.06%. Farah Champsi also owns 1,714,330 shares of Chimerix Inc (CMRX) as of October 23, 2013, with a value of $2 Million and a weighting of 12.94%.

Latest Holdings of Farah Champsi

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KITE	Kite Pharma Inc	2017-06-16	63,664	179.79	11,446,151
CMRX	Chimerix Inc	2013-10-23	1,714,330	0.99	1,701,301

Holding Weightings of Farah Champsi

Farah Champsi Form 4 Trading Tracker

According to the SEC Form 4 filings, Farah Champsi has made a total of 0 transactions in Kite Pharma Inc (KITE) over the past 5 years. The most-recent trade in Kite Pharma Inc is the sale of 20,450 shares on June 16, 2017, which brought Farah Champsi around $2 Million.

According to the SEC Form 4 filings, Farah Champsi has made a total of 0 transactions in Chimerix Inc (CMRX) over the past 5 years. The most-recent trade in Chimerix Inc is the sale of 447,499 shares on October 23, 2013, which brought Farah Champsi around $7 Million.

Insider Trading History of Farah Champsi

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Farah Champsi Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Farah Champsi Ownership Network

Ownership Network List of Farah Champsi

No Data

Ownership Network Relation of Farah Champsi

Farah Champsi Owned Company Details

What does Allakos Inc do?

Who are the key executives at Allakos Inc?

Farah Champsi is the 10 percent owner of Allakos Inc. Other key executives at Allakos Inc include Chief Financial Officer Harlan Baird Radford , Chief Medical Officer Craig A. Paterson , and General Counsel and Secretary Margaret Nell Fitzgerald .

Allakos Inc (ALLK) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Allakos Inc (ALLK). Other recent insider transactions involving Allakos Inc (ALLK) include a net sale of 87,064 shares made by Harlan Baird Radford ,

In summary, during the past 3 months, insiders sold 0 shares of Allakos Inc (ALLK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 87,064 shares of Allakos Inc (ALLK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 87,064 shares.

Allakos Inc (ALLK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Allakos Inc Insider Transactions

No Available Data

What does Sutro Biopharma Inc do?

Who are the key executives at Sutro Biopharma Inc?

Farah Champsi is the 10 percent owner of Sutro Biopharma Inc. Other key executives at Sutro Biopharma Inc include Chief Port. Strat & Alnce Ofcr Nicki Vasquez , Chief Scientific Officer Hans-peter Gerber , and Chief Business Officer Brunilda Shtylla .

Sutro Biopharma Inc (STRO) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Sutro Biopharma Inc (STRO). Other recent insider transactions involving Sutro Biopharma Inc (STRO) include a net sale of 27,041 shares made by Brunilda Shtylla , and a net sale of 12,185 shares made by Nicki Vasquez .

In summary, during the past 3 months, insiders sold 0 shares of Sutro Biopharma Inc (STRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 39,226 shares of Sutro Biopharma Inc (STRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 39,226 shares.

Sutro Biopharma Inc (STRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sutro Biopharma Inc Insider Transactions

No Available Data

What does Kite Pharma Inc do?

Who are the key executives at Kite Pharma Inc?

Farah Champsi is the director of Kite Pharma Inc. Other key executives at Kite Pharma Inc include Chief Commercial Officer Shawn Tomasello , EVP & Business Development Helen Susan Kim , and EVP & Technical Operations Timothy L. Moore .

Kite Pharma Inc (KITE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kite Pharma Inc (KITE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kite Pharma Inc (KITE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kite Pharma Inc (KITE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kite Pharma Inc Insider Transactions

No Available Data

What does Evofem Biosciences Inc do?

Who are the key executives at Evofem Biosciences Inc?

Farah Champsi is the 10 percent owner of Evofem Biosciences Inc. Other key executives at Evofem Biosciences Inc include Chief Financial Officer Yan Zhang , director & 10 percent owner Kim P. Kamdar , and Chief Commercial Officer Atkinson Katherine Cocca .

Evofem Biosciences Inc (EVFM) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Evofem Biosciences Inc (EVFM). Other recent insider transactions involving Evofem Biosciences Inc (EVFM) include a net sale of 104 shares made by Yan Zhang , and a net sale of 10 shares made by Kim P. Kamdar .

In summary, during the past 3 months, insiders sold 0 shares of Evofem Biosciences Inc (EVFM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 114 shares of Evofem Biosciences Inc (EVFM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 114 shares.

Evofem Biosciences Inc (EVFM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Evofem Biosciences Inc Insider Transactions

No Available Data

What does ZS Pharma Inc do?

Who are the key executives at ZS Pharma Inc?

Farah Champsi is the 10 percent owner of ZS Pharma Inc. Other key executives at ZS Pharma Inc include 10 percent owner Devon Park Associates, Llc , Chief Operating Officer D Jeffrey Keyser , and See Remarks Adam Tomasi .

ZS Pharma Inc (ZSPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZS Pharma Inc (ZSPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZS Pharma Inc (ZSPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZS Pharma Inc (ZSPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZS Pharma Inc Insider Transactions

No Available Data

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Farah Champsi is the 10 percent owner of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .

aTyr Pharma Inc (ATYR) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in aTyr Pharma Inc (ATYR). Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 65,000 shares made by Sanjay Shukla , a net purchase of 3,410 shares made by Jill Marie Broadfoot , and a net purchase of 100,000 shares made by Paul Schimmel .

In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,590 shares of aTyr Pharma Inc (ATYR) were sold and 225,000 shares were bought by its insiders, resulting in a net purchase of 223,410 shares.

aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.

aTyr Pharma Inc Insider Transactions

No Available Data

What does Trevena Inc do?

Who are the key executives at Trevena Inc?

Farah Champsi is the director & 10 percent owner of Trevena Inc. Other key executives at Trevena Inc include SVP & Chief Medical Officer Mark Demitrack , SVP & Chief Business Officer Robert T Yoder , and director & President & CEO Carrie L. Bourdow .

Trevena Inc (TRVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Trevena Inc (TRVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Trevena Inc (TRVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Trevena Inc (TRVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Trevena Inc Insider Transactions

No Available Data

What does Applied Genetic Technologies Corp do?

Who are the key executives at Applied Genetic Technologies Corp?

Farah Champsi is the 10 percent owner of Applied Genetic Technologies Corp. Other key executives at Applied Genetic Technologies Corp include Chief Medical Officer Susan Schneider , Chief Financial Officer Jonathan I Lieber , and See Remarks Stephen W Potter .

Applied Genetic Technologies Corp (AGTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Applied Genetic Technologies Corp (AGTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Applied Genetic Technologies Corp (AGTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Applied Genetic Technologies Corp (AGTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Applied Genetic Technologies Corp Insider Transactions

No Available Data

What does Esperion Therapeutics Inc do?

Who are the key executives at Esperion Therapeutics Inc?

Farah Champsi is the 10 percent owner of Esperion Therapeutics Inc. Other key executives at Esperion Therapeutics Inc include Chief Commercial Officer Eric Warren , Chief Operating Officer Sheldon L. Koenig , and Chief Medical Officer Joanne M. Foody .

Esperion Therapeutics Inc (ESPR) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Esperion Therapeutics Inc (ESPR). Other recent insider transactions involving Esperion Therapeutics Inc (ESPR) include a net sale of 7,679 shares made by Eric Warren , a net sale of 4,202 shares made by Joanne M. Foody , and a net sale of 14,550 shares made by Sheldon L. Koenig .

In summary, during the past 3 months, insiders sold 17,476 shares of Esperion Therapeutics Inc (ESPR) in total and bought 0 shares, with a net sale of 17,476 shares. During the past 18 months, 26,431 shares of Esperion Therapeutics Inc (ESPR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 26,431 shares.

Esperion Therapeutics Inc (ESPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Esperion Therapeutics Inc Insider Transactions

No Available Data

What does Immune Design Corp do?

Who are the key executives at Immune Design Corp?

Farah Champsi is the 10 percent owner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .

Immune Design Corp (IMDZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immune Design Corp Insider Transactions

No Available Data

What does SCYNEXIS Inc do?

Who are the key executives at SCYNEXIS Inc?

Farah Champsi is the 10 percent owner of SCYNEXIS Inc. Other key executives at SCYNEXIS Inc include Chief Medical Officer Gonzalez David Angulo , Chief Financial Officer Ivor Macleod , and General Counsel Scott Sukenick .

SCYNEXIS Inc (SCYX) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in SCYNEXIS Inc (SCYX). Other recent insider transactions involving SCYNEXIS Inc (SCYX) include a net purchase of 20,000 shares made by Gonzalez David Angulo ,

In summary, during the past 3 months, insiders sold 0 shares of SCYNEXIS Inc (SCYX) in total and bought 20,000 shares, with a net purchase of 20,000 shares. During the past 18 months, 0 shares of SCYNEXIS Inc (SCYX) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 20,000 shares.

SCYNEXIS Inc (SCYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

SCYNEXIS Inc Insider Transactions

No Available Data

What does Cara Therapeutics Inc do?

Who are the key executives at Cara Therapeutics Inc?

Farah Champsi is the 10 percent owner of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .

Cara Therapeutics Inc (CARA) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Cara Therapeutics Inc (CARA). Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 60,412 shares made by Christopher Posner , a net sale of 5,476 shares made by Joana Goncalves , and a net sale of 5,236 shares made by Scott Terrillion .

In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 74,117 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 74,117 shares.

Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cara Therapeutics Inc Insider Transactions

No Available Data

What does Chimerix Inc do?

Who are the key executives at Chimerix Inc?

Farah Champsi is the director & 10 percent owner of Chimerix Inc. Other key executives at Chimerix Inc include Chief Business Officer Michael T. Andriole , Principal Accounting Officer David Jakeman , and director & Chief Executive Officer Michael A. Sherman .

Chimerix Inc (CMRX) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Chimerix Inc (CMRX). Other recent insider transactions involving Chimerix Inc (CMRX) include a net purchase of 40,000 shares made by Fred A Middleton , a net sale of 6,270 shares made by David Jakeman , and a net sale of 3,029 shares made by Michael T. Andriole .

In summary, during the past 3 months, insiders sold 0 shares of Chimerix Inc (CMRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,239 shares of Chimerix Inc (CMRX) were sold and 40,000 shares were bought by its insiders, resulting in a net purchase of 28,761 shares.

Chimerix Inc (CMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chimerix Inc Insider Transactions

No Available Data

What does Portola Pharmaceuticals Inc do?

Who are the key executives at Portola Pharmaceuticals Inc?

Farah Champsi is the director of Portola Pharmaceuticals Inc. Other key executives at Portola Pharmaceuticals Inc include EVP & General Counsel John B Moriarty , EVP and CFO Mardi Dier , and EVP & CMO Rajiv Patni .

Portola Pharmaceuticals Inc (PTLA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Portola Pharmaceuticals Inc (PTLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Portola Pharmaceuticals Inc (PTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Portola Pharmaceuticals Inc (PTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Portola Pharmaceuticals Inc Insider Transactions

No Available Data

What does Aegerion Pharmaceuticals Inc do?

Who are the key executives at Aegerion Pharmaceuticals Inc?

Farah Champsi is the 10 percent owner of Aegerion Pharmaceuticals Inc. Other key executives at Aegerion Pharmaceuticals Inc include director & Chief Executive Officer Mary T Szela , other: See Remarks Gregory D Perry , and 10 percent owner Broadfin Healthcare Master Fund Ltd .

Aegerion Pharmaceuticals Inc (AEGR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aegerion Pharmaceuticals Inc (AEGR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aegerion Pharmaceuticals Inc (AEGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aegerion Pharmaceuticals Inc (AEGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aegerion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Farah Champsi is the other: Former 10% Owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Corcept Therapeutics Inc do?

Who are the key executives at Corcept Therapeutics Inc?

Farah Champsi is the 10 percent owner of Corcept Therapeutics Inc. Other key executives at Corcept Therapeutics Inc include Chief Development Officer William Guyer , CHIEF FINANCIAL OFFICER Gary Charles Robb , and Chief Accounting Officer Joseph Douglas Lyon .

Corcept Therapeutics Inc (CORT) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Corcept Therapeutics Inc (CORT). Other recent insider transactions involving Corcept Therapeutics Inc (CORT) include a net sale of 70,000 shares made by Joseph Douglas Lyon , a net sale of 28,750 shares made by Swisher Daniel N Jr , and a net sale of 225,000 shares made by Sean Maduck .

In summary, during the past 3 months, insiders sold 44,101 shares of Corcept Therapeutics Inc (CORT) in total and bought 0 shares, with a net sale of 44,101 shares. During the past 18 months, 517,899 shares of Corcept Therapeutics Inc (CORT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 517,899 shares.

Corcept Therapeutics Inc (CORT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corcept Therapeutics Inc Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Farah Champsi is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Raptor Pharmaceutical Corp do?

Who are the key executives at Raptor Pharmaceutical Corp?

Farah Champsi is the other: No longer 10% owner of Raptor Pharmaceutical Corp. Other key executives at Raptor Pharmaceutical Corp include Chief Medical Officer Krishna R Polu , Chief Financial Officer Michael P Smith , and Chief Commercial Officer David Happel .

Raptor Pharmaceutical Corp (RPTP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Raptor Pharmaceutical Corp (RPTP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Raptor Pharmaceutical Corp (RPTP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Raptor Pharmaceutical Corp (RPTP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Raptor Pharmaceutical Corp Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Farah Champsi is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Farah Champsi is the other: See footnotes of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Farah Champsi is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Farah Champsi made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 14,272 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,272 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 85,728 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

What does Population Health Investment Co Inc do?

Who are the key executives at Population Health Investment Co Inc?

Farah Champsi is the director of Population Health Investment Co Inc. Other key executives at Population Health Investment Co Inc include director & Chief Executive Officer Clive Meanwell , director & Executive Chairman Ian C Read , and Senior Vice President Christopher T Cox .

Population Health Investment Co Inc (PHIC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Population Health Investment Co Inc (PHIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Population Health Investment Co Inc (PHIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Population Health Investment Co Inc (PHIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Population Health Investment Co Inc Insider Transactions

No Available Data

What does Population Health Investment Co Inc do?

Who are the key executives at Population Health Investment Co Inc?

Farah Champsi is the director of Population Health Investment Co Inc. Other key executives at Population Health Investment Co Inc include director & Executive Chairman Ian C Read , Senior Vice President Christopher T Cox , and director & Chief Executive Officer Clive Meanwell .

Population Health Investment Co Inc (PHICU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Population Health Investment Co Inc (PHICU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Population Health Investment Co Inc (PHICU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Population Health Investment Co Inc (PHICU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Population Health Investment Co Inc Insider Transactions

No Available Data

Farah Champsi Mailing Address

Above is the net worth, insider trading, and ownership report for Farah Champsi. You might contact Farah Champsi via mailing address: One Embarcadero Center Suite 3700, San Francisco Ca 94111.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.